7Baggers

We provide you with 20 years of free, institutional-grade data for AMAM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AMAM. Explore the full financial landscape of AMAM stock.

Reported DateCIKTickerType
2023-08-091836056AMAM10-QUrl
2023-05-111836056AMAM10-QUrl
2023-03-301836056AMAM10-KUrl
2022-12-161836056AMAM6-KUrl
2022-12-131836056AMAM6-KUrl
2022-11-011836056AMAM6-KUrl
2022-10-181836056AMAM6-KUrl
2022-08-291836056AMAM6-KUrl
2022-08-291836056AMAM6-KUrl
2022-08-161836056AMAM6-KUrl
2022-07-051836056AMAM6-KUrl
2022-06-061836056AMAM6-KUrl
2022-05-171836056AMAM6-KUrl
2022-04-261836056AMAM20-FUrl
2022-04-261836056AMAM6-KUrl
2022-02-071836056AMAM6-KUrl
2022-01-041836056AMAM6-KUrl
2021-12-091836056AMAM6-KUrl
2021-11-221836056AMAM6-KUrl
2021-11-081836056AMAM6-KUrl
2021-10-281836056AMAM6-KUrl
2021-10-281836056AMAM6-KUrl
2021-10-041836056AMAM6-KUrl
2021-07-021836056AMAM6-KUrl

Ambrx Biopharma Inc
(NASDAQ:AMAM) 

AMAM stock logo

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system.

Founded: 2003
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology

Share this website to your friends
The information provided in this report about AMAM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.